A class action lawsuit has been filed against VistaGen Therapeutics Inc. on behalf of investors who purchased the company’s common stock between April 1, 2024 and December 16, 2025. The litigation alleges that VistaGen made false and misleading statements regarding the viability of its Phase 3 PALISADE-3 trial study of fasedienol, a treatment for social anxiety disorder. According to the complaint, the company failed to disclose material adverse facts about the trial, which ultimately did not meet its primary or secondary endpoints. Following the announcement of the trial results on December 17, 2025, VistaGen’s stock price fell by more than 80%. Shareholders who suffered losses during the class period may be eligible to participate in the litigation and have until March 16, 2026 to seek appointment as lead plaintiff. All representation is on a contingency fee basis, with no fees or expenses required from shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602131317PRIMZONEFULLFEED9654663) on February 13, 2026, and is solely responsible for the information contained therein.